Insider
Moderna, Inc.MRNA

Moderna appoints Juan Andres as chief operating officer and expands its vaccine portfolio

Moderna announced the appointment of Juan Andres as chief operating officer, effective Oct. 5, 2026, with a base salary of $800,000, a cash bonus target of up to 90% of salary and a new equity grant worth $5,000,000. At the same time, the company said Jerh Collins, chief technical operations and quality officer, will retire, and that its infectious disease franchise now includes five approved vaccines, adding a seasonal flu shot approved by the U.S. FDA and a flu‑COVID combination vaccine cleared by the European Commission.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white wooden desk on hallway inside building
Photo by Brandon Holmes on Unsplash
$5,000,000
Equity grant
$800,000
Base salary
5
Approved vaccines

Key points

  • Moderna said Juan Andres will become chief operating officer on Oct.
  • Moderna said the new chief operating officer role was created to support the company's expanding scale and diversification, and that the portfolio expansion reflects recent regulator approvals that enable new vaccine offerings.
  • Juan Andres’s appointment and compensation do not guarantee higher financial results.

What happened

Moderna said Juan Andres will become chief operating officer on Oct. 5, 2026. Under his agreement he will receive a $800,000 annual base salary, a cash bonus with a target of 90% of salary and a $5,000,000 equity grant that vests over four years.

The company also disclosed that Jerh Collins, chief technical operations and quality officer, will retire, and that the infectious disease franchise has grown to five approved vaccines after the FDA approved Moderna’s seasonal flu vaccine and the European Commission authorized its seasonal flu‑plus‑COVID combination vaccine.

Compensation terms for the new chief operating officer

Base salary
$800,000
Equity grant
$5,000,000
Data from the original sources listed alongside.

Company explanation

Moderna said the new chief operating officer role was created to support the company's expanding scale and diversification, and that the portfolio expansion reflects recent regulator approvals that enable new vaccine offerings.

What this does not mean

Juan Andres’s appointment and compensation do not guarantee higher financial results. Jerh Collins’s retirement does not necessarily cause production disruptions, though it will be monitored. The broader vaccine portfolio creates revenue potential only if demand remains stable and is not proof of immediate profit.

Original sources

  1. 8-K filing, September 30, 2026September 30, 2026SHA-256 of our archived copy 873bd79b9696…
  2. 8-K EX-99.1 filing, September 30, 2026September 30, 2026SHA-256 of our archived copy 485f824c965d…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards